Search Results - "Brotchie, Jonathan M."

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease by Huot, Philippe, Johnston, Tom H, Koprich, James B, Fox, Susan H, Brotchie, Jonathan M

“…L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term administration of L-DOPA…”
Get full text

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque by Koprich, James B, Johnston, Tom H, Reyes, Gabriela, Omana, Vanessa, Brotchie, Jonathan M

“…Recent failures in clinical trials for disease modification in Parkinson's disease have highlighted the need for a non-human primate model of the…”
Get full text

Levodopa-induced dyskinesias by Fabbrini, Giovanni, Brotchie, Jonathan M., Grandas, Francisco, Nomoto, Masahiro, Goetz, Christopher G.

“…Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and…”
Get full text

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials by Kalia, Lorraine V., Brotchie, Jonathan M., Fox, Susan H.

“…Neurotransmitters other than dopamine are recognized as having modulatory roles within the basal ganglia and can influence the basal ganglia dopaminergic…”
Get full text

Serotonin and Parkinson's disease: On movement, mood, and madness by Fox, Susan H., Chuang, Rosalind, Brotchie, Jonathan M.

“…An appreciation of the multiple roles that serotonin (5‐HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in…”
Get full text

Nondopaminergic mechanisms in levodopa-induced dyskinesia by Brotchie, Jonathan M.

“…It has become increasingly apparent that Parkinson's disease involves many transmitter systems other than dopamine. This nondopaminergic involvement impacts on…”
Get full text

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease by Grotemeyer, Alexander, Fischer, Judith F, Koprich, James B, Brotchie, Jonathan M, Blum, Robert, Volkmann, Jens, Ip, Chi Wang

“…Neuroinflammation has been suggested as a pathogenetic mechanism contributing to Parkinson's disease (PD). However, anti-inflammatory treatment strategies have…”
Get full text

Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease by McFleder, Rhonda L., Makhotkina, Anastasiia, Groh, Janos, Keber, Ursula, Imdahl, Fabian, Peña Mosca, Josefina, Peteranderl, Alina, Wu, Jingjing, Tabuchi, Sawako, Hoffmann, Jan, Karl, Ann-Kathrin, Pagenstecher, Axel, Vogel, Jörg, Beilhack, Andreas, Koprich, James B., Brotchie, Jonathan M., Saliba, Antoine-Emmanuel, Volkmann, Jens, Ip, Chi Wang

“…Inflammation in the brain and gut is a critical component of several neurological diseases, such as Parkinson’s disease (PD). One trigger of the immune system…”
Get full text

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice by Badr, Mohammad, McFleder, Rhonda L, Wu, Jingjing, Knorr, Susanne, Koprich, James B, Hünig, Thomas, Brotchie, Jonathan M, Volkmann, Jens, Lutz, Manfred B, Ip, Chi Wang

“…Regulatory CD4 CD25 FoxP3 T cells (Treg) are a subgroup of T lymphocytes involved in maintaining immune balance. Disturbance of Treg number and impaired…”
Get full text

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future by Fox, Susan H, Brotchie, Jonathan M

“…Non-human primate (NHP) models of Parkinson's disease (PD) have been essential in understanding the pathophysiology and neural mechanisms underlying PD. The…”
Get more information

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein by McKinnon, Chris, De Snoo, Mitchell L, Gondard, Elise, Neudorfer, Clemens, Chau, Hien, Ngana, Sophie G, O'Hara, Darren M, Brotchie, Jonathan M, Koprich, James B, Lozano, Andres M, Kalia, Lorraine V, Kalia, Suneil K

“…Parkinson's disease is a progressive neurodegenerative disorder characterised by the accumulation of misfolded α-synuclein in selected brain regions, including…”
Get full text

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l -DOPA induced dyskinesia in mouse models by Thiele, Sherri L, Chen, Betty, Lo, Charlotte, Gertler, Tracey S, Warre, Ruth, Surmeier, James D, Brotchie, Jonathan M, Nash, Joanne E

“…Abstract Parkinsonian symptoms arise due to over-activity of the indirect striatal output pathway, and under-activity of the direct striatal output pathway. l…”
Get full text

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism by Gleave, Jacqueline A., Arathoon, Lindsay R., Trinh, Dennison, Lizal, Kristin E., Giguère, Nicolas, Barber, James H.M., Najarali, Zainab, Khan, M. Hassan, Thiele, Sherri L., Semmen, Mahin S., Koprich, James B., Brotchie, Jonathan M., Eubanks, James H., Trudeau, Louis-Eric, Nash, Joanne E.

“…Parkinson's disease (PD) is a neurodegenerative movement disorder, which affects approximately 1–2% of the population over 60years of age. Current treatments…”
Get full text

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease by Johnston, Tom H, Fox, Susan H, McIldowie, Matthew J, Piggott, Matthew J, Brotchie, Jonathan M

“…Long-term motor complications of dopamine replacement, such as L-DOPA-induced dyskinesia (LID) and reduced quality of L-DOPA action, remain obstacles in the…”
Get more information

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease by Titze-de-Almeida, Simoneide S, Soto-Sánchez, Cristina, Fernandez, Eduardo, Koprich, James B, Brotchie, Jonathan M, Titze-de-Almeida, Ricardo

“…MicroRNAs (miRNAs) are small double-stranded RNAs that exert a fine-tuning sequence-specific regulation of cell transcriptome. While one unique miRNA regulates…”
Get full text

Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease by Matschke, Lina A., Komadowski, Marlene A., Stöhr, Annette, Lee, Bolam, Henrich, Martin T., Griesbach, Markus, Rinné, Susanne, Geibl, Fanni F., Chiu, Wei-Hua, Koprich, James B., Brotchie, Jonathan M., Kiper, Aytug K., Dolga, Amalia M., Oertel, Wolfgang H., Decher, Niels

“…Parkinson’s disease (PD) is clinically defined by the presence of the cardinal motor symptoms, which are associated with a loss of dopaminergic nigrostriatal…”
Get full text

Non-dopaminergic treatments in development for Parkinson's disease by Fox, Susan H, MRCP, Brotchie, Jonathan M, PhD, Lang, Anthony E, MD

“…Summary Non-dopaminergic treatments are increasingly being recognised as part of the therapeutic armamentarium for Parkinson's disease (PD). Clinical and…”
Get full text

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? by Huot, Philippe, Fox, Susan H, Newman-Tancredi, Adrian, Brotchie, Jonathan M

“…L-DOPA remains the most effective treatment for Parkinson's disease (PD). However, long-term administration of L-DOPA is compromised by complications,…”
Get more information

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein by Koprich, James B, Johnston, Tom H, Huot, Philippe, Reyes, M Gabriela, Espinosa, Maria, Brotchie, Jonathan M

“…The pathological hallmarks of Parkinson's disease (PD) are degeneration of dopamine (DA) neurons of the substantia nigra (SN) and the presence of…”
Get full text

Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies by Bezard, Erwan, Brotchie, Jonathan M, Gross, Christian E

“…Involuntary movements--or dyskinesias--are a debilitating complication of levodopa therapy for Parkinson's disease, and is experienced in most patients…”
Get full text